Comparative Pharmacology
Head-to-head clinical analysis: POVAN versus STROMECTOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POVAN versus STROMECTOL.
POVAN vs STROMECTOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pyrvinium pamoate inhibits oxidative metabolism and glucose uptake in susceptible helminths, leading to energy depletion and paralysis of the worm. It also binds to DNA and inhibits RNA synthesis in the parasite.
Ivermectin acts by binding selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased permeability to chloride ions, hyperpolarization of nerve or muscle cells, and death of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA).
Pyrantel pamoate: 11 mg/kg (maximum 1 g) orally once; repeat in 2 weeks for pinworm. For ascariasis, hookworm, trichostrongyliasis: 11 mg/kg (max 1 g) once daily for 3 days.
Oral: 200 mcg/kg once daily for 1-2 days. For strongyloidiasis, 200 mcg/kg/day for 2 days. For onchocerciasis, single dose of 150 mcg/kg.
None Documented
None Documented
Terminal elimination half-life is approximately 16 hours; clinically, this supports single-dose administration with slow elimination
Terminal elimination half-life is approximately 18 hours (range 10–30 hours) in healthy subjects; prolonged in hepatic impairment.
Primarily fecal (90%) as unchanged drug via bile; renal excretion is minimal (<1%)
Primarily fecal (90%) as unchanged drug and metabolites; renal excretion accounts for <1% of the dose.
Category C
Category C
Anthelmintic
Anthelmintic